Expert Interview
Discussing the potential of INV-202 (Monlunabant), a CB1 antagonist currently in development by Novo Nordisk for weight loss
Ticker(s): NVO, LLY, CRBPInstitution: University Clinic Salzburg
- Professor of Pediatrics at Paracelsus Medical School in Salzburg, Austria
- Manages 500+ child/adolescent patients with Obesity
- Research and clinical interest in metabolic comorbidities including glucose and fat metabolism
Can you provide background information about your expertise and current practice setting?
What is your current standard of care for treating obesity, and how has it evolved over the past few years?
What are your thoughts on the CB1 antagonist class, specifically the potential of monlunabant and its mechanism?
What level of weight loss and safety profile would make an oral CB1 antagonist viable compared to current treatments like GLP-1s?
Added By: slingshot_insightsHow would you rate your overall excitement and where do you see monlunabant fitting into the treatment algorithm for obesity?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
